局部晚期鼻咽癌诱导化疗加IMRT同期化疗与IMRT同期化疗的远期疗效比较

Objective To compare the long-term efficacy between two radiochemotherapy regimens for locally advanced nasopharyngeal carcinoma (NPC):intensity-modulated radiotherapy with concurrent chemotherapy (CCRT) versus neoadjuvant chemotherapy (NACT) followed by CCRT. Methods A retrospective analysis was performed on the clinical data of 278 patients with locally advanced NPC who were admitted to our hospital from 2001 to 2008. Of the 278 patients, 133 received CCRT, and 145 received NACT followed by CCRT (NACT+CCRT). Results The follow-up rate was 96.6%. The 5-year overall survival (OS), distant metastasis-free survival (DMFS), recurrence-free survival (RFS), and progression-free survival (PFS) were 78.1%, 78.0%, 90.6%, and 72.0%, respectively. There were no significant differences between the CCRT group and NACT+CCRT group in 5-year OS (79.9% vs. 76.4%, P=0.443), DMFS (77.1% vs. 78.9%, P=0.972), RFS (91.6% vs. 89.8%, P=0.475), and PFS (71.6% vs. 72.2%, P=0.731). Subgroup analysis showed that compared with CCRT, NACT+CCRT did not significantly improve 5-year RFS in T_3-4N_0-1 patients (90.7% vs. 86.9%, P=0.376) and did not significantly improve 5-year DMFS in patients with advanced N-stage disease (57.6% vs. 69.7%, P=0.275). There were significantly higher numbers of individuals with neutropenia, decrease in hemoglobin, and upper gastrointestinal reactions in patients treated with NACT+CCRT than in those treated with CCRT (100 vs. 52, P=0.000;64 vs. 35, P=0.010;90 vs. 63, P=0.044). Conclusions Compared with CCRT, NACT+CCRT does not significantly improve the prognosis in patients with locally advanced NPC and leads to significant increases in grade ≥3 toxicities (neutropenia, decrease in hemoglobin, and upper gastrointestinal reactions). The role of NACT in the treatment of locally advanced NPC needs further study
DOI:10.3760/cma.j.issn.1004-4221.2014.02.013
作者单位:510060 广州,华南肿瘤学国家重点实验室中山大学肿瘤防治中心放疗科
通信作者:卢泰祥,Email:lutx@mail.sysu.edu.cn

Comparison of long-term efficacy between intensity-modulated radiotherapy with concurrent chemotherapy and neoadjuvant chemotherapy followed by intensity-modulated radiotherapy with concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma